secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0000078003-24-000103
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer Q1 revenue $14.9B (-20% YoY); adj. EPS $0.82; raises FY adj. EPS guidance
--------------------------------------------------------------------------------

- Q1 revenue $14.9B, operational decline 19% YoY; ex-COVID products grew 11% operationally.
- Reported diluted EPS $0.55; adjusted diluted EPS $0.82 (includes $0.11 favorable Paxlovid return adjustment).
- Full-year 2024 revenue guidance reaffirmed at $58.5-$61.5B; adjusted EPS guidance raised to $2.15-$2.35.
- Cost realignment program on track to deliver at least $4 billion net cost savings by end of 2024.
- Notable approvals: Beqvez (hemophilia B) FDA approval, Prevenar 20 (pediatrics) EU approval, Tivdak full FDA approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800324000103/0000078003-24-000103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800324000103/pfe-20240501.htm
  HTML page:      https://secwatch.observer/filing/0000078003-24-000103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer